% Created 2019-11-06 Wed 17:02
% Intended LaTeX compiler: pdflatex
\documentclass[presentation, smaller]{beamer}
\usepackage[utf8]{inputenc}
\usepackage[T1]{fontenc}
\usepackage{graphicx}
\usepackage{grffile}
\usepackage{longtable}
\usepackage{wrapfig}
\usepackage{rotating}
\usepackage[normalem]{ulem}
\usepackage{amsmath}
\usepackage{textcomp}
\usepackage{amssymb}
\usepackage{capt-of}
\usepackage{hyperref}
\hypersetup{colorlinks,linkcolor=white,urlcolor=blue}
\usepackage{textpos}
\usepackage{textgreek}
\usepackage[version=4]{mhchem}
\usepackage{chemfig}
\usepackage{siunitx}
\usepackage{gensymb}
\usepackage[usenames,dvipsnames]{xcolor}
\usepackage[T1]{fontenc}
\usepackage{lmodern}
\usepackage{verbatim}
\usepackage{tikz}
\usepackage{wasysym}
\usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
\usetheme{Hannover}
\usecolortheme{whale}
\author{Matthew Henderson, PhD, FCACB}
\date{\today}
\title{Congenital Disorders of N-Linked Glycosylation}
\institute[NSO]{Newborn Screening Ontario | The University of Ottawa}
\titlegraphic{\includegraphics[height=1cm,keepaspectratio]{../logos/NSO_logo.pdf}\includegraphics[height=1cm,keepaspectratio]{../logos/cheo-logo.png} \includegraphics[height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}}
\hypersetup{
 pdfauthor={Matthew Henderson, PhD, FCACB},
 pdftitle={Congenital Disorders of N-Linked Glycosylation},
 pdfkeywords={},
 pdfsubject={},
 pdfcreator={Emacs 26.1 (Org mode 9.1.9)}, 
 pdflang={English}}
\begin{document}

\maketitle

%\logo{\includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/NSO_logo_small.pdf}~%
%    \includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}%
%}

\vspace{220pt}
\beamertemplatenavigationsymbolsempty
\setbeamertemplate{caption}[numbered]
\setbeamerfont{caption}{size=\tiny}
% \addtobeamertemplate{frametitle}{}{%
% \begin{textblock*}{100mm}(.85\textwidth,-1cm)
% \includegraphics[height=1cm,width=2cm]{cat}
% \end{textblock*}}

\section{Disorders of Protein N-Glycosylation}
\label{sec:orgd8c4958}
\begin{frame}[label={sec:org7061ec2}]{Introduction}
\begin{itemize}
\item Most extracellular proteins, membrane proteins and several
intracellular proteins (lysosomal enzymes), are glycoproteins.

\item The glycans are defined by their linkage to the protein:
\begin{itemize}
\item N-glycans are linked to the amide group of asparagine
\item O-glycans are linked to the hydroxyl group of serine or
threonine.
\end{itemize}

\item Congenital disorders of glycosylation are due to defects in the
synthesis of glycans and in the attachment of glycans to proteins
and lipids.
\item Rapidly growing disease family (N-,O-,GPI) \textasciitilde{}60 (listed on NORD)
\begin{itemize}
\item 1\% of HG involved in glycosylation
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:orgbd9805b}]{Synthesis of N-glycans}
\begin{enumerate}
\item Formation in the cytosol of nucleotide-linked sugars
\begin{itemize}
\item mainly GDP-Man, UDP-Glc and UDP-GlcNAc
\item attachment of GlcNAc and Man units to dolichol phosphate
\item flipping into the ER
\end{itemize}
\item Stepwise assembly in the ER
\begin{itemize}
\item addition of Man and Glc \(\to\) 14-unit oligosaccharide precuror:
\begin{itemize}
\item dolichol pyrophosphate-N-acetyl-glucosamine\(_{\text{2}}\)-mannose\(_{\text{9}}\)-glucose\(_{\text{3}}\)
\end{itemize}
\end{itemize}
\item Transfer of this precursor onto the nascent protein
\begin{itemize}
\item processing of the glycan in the Golgi apparatus
\begin{itemize}
\item trimming and attachment of various sugar units
\end{itemize}
\end{itemize}
\end{enumerate}
\end{frame}

\begin{frame}[label={sec:org7aa24f7}]{N-glycan Assembly}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./figures/glyc.png}
\caption{\label{fig:org2a382c6}
N-glycan assembly}
\end{figure}
\end{frame}


\begin{frame}[label={sec:org2e24bf5}]{N-glycan Assembly}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./figures/ngassembly.png}
\caption{\label{fig:org7296e42}
N-glycan assembly}
\end{figure}
\end{frame}

\begin{frame}[label={sec:orgdbe7e3f}]{N-glycan Remodelling}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./figures/ngremodel.png}
\caption{\label{fig:orgc4a2202}
N-glycan remodelling}
\end{figure}
\end{frame}

\begin{frame}[label={sec:org1b497ae}]{CDG}
\begin{itemize}
\item very broad spectrum of clinical manifestations
\item considered in any unexplained clinical condition
\begin{itemize}
\item particularly in multi-organ disease with neurological involvement
\item non-specific developmental disability is the only presenting sign
\end{itemize}
\item Incidence 1:50,000 to 100,000 births
\end{itemize}
\end{frame}

\begin{frame}[label={sec:orgc8200aa}]{CDG classification}
\begin{itemize}
\item Each CDG type is defined by a specific enzyme defect and the mutation in its underlying gene
\item Most CDG mutations are hypomorphic and allow some glycan synthesis
\item Type 1: ER defects
\item Type 2: Golgi defects
\item \textasciitilde{}1500+ cases worldwide
\item \textasciitilde{}300+ cases in the US
\begin{itemize}
\item 70\% PMM2-CDG
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:org80437e8}]{Transferrin IEF}
\begin{itemize}
\item serum transferrin IEF is still the screening method of choice
\begin{itemize}
\item able to detect only a limited number of CDGs
\item N-glycosylation disorders associated with sialic acid deficiency
\end{itemize}

\item Normal serum transferrin is mainly composed of tetrasialotransferrin
and small amounts of mono-, di-, tri-, penta- and
hex-asialotransferrins.

\item Partial deficiency of sialic acid (-ve charge) causes a
cathodal shift.

\item Two main types of cathodal shift can be recognized:
\begin{itemize}
\item Type 1 or 2 patterns
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:orgd1a0830}]{Transferrin IEF}
\begin{itemize}
\item A Type 1 pattern is characterized by an increase of both disialo- and
asialotransferrin and a decrease of tetra-, penta-and
hexasialotransferrins;

\begin{itemize}
\item defects in the assembly of the dolichol lipid-linked oligosaccharide (LLO) chain
and its transfer to the nascent protein,
\item PMM2-CDG or MPI-CDG should be considered first
\end{itemize}

\item A Type 1 pattern is also seen in secondary glycosylation disorders
such as chronic alcoholism, hereditary fructose intolerance and
galactosaemia.

\item In a Type 2 pattern there is also an increase of the tri- \textpm{}
monosialotransferrin bands.

\begin{itemize}
\item defects in the trimming and processing of the protein-bound
glycans either late in the endoplasmic reticulum or the Golgi
compartments.
\end{itemize}

\item A shift due to a transferrin protein variant has first to be excluded
\begin{itemize}
\item IEF after neuraminidase treatment, study of another glycoprotein
or, investigation of the parents.
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:orgd7f12a3}]{Additional Laboratory Investigations}
\begin{itemize}
\item Protein-linked glycan analysis can be performed to identify the defective step
\begin{itemize}
\item MALDI-TOF analysis of released N-linked oligosaccharides
\end{itemize}
\item CDG gene panel analysis or WES.

\item Capillary zone electrophoresis of total serum is a rapid screening
test for CDG.
\begin{itemize}
\item An abnormal result should be further investigated by serum
transferrin IEF.
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:orgde8c3fb}]{Transferrin IEF}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./figures/transferrin_ief.png}
\caption{\label{fig:orgd4a157a}
Transferrin IEF}
\end{figure}
\end{frame}


\begin{frame}[label={sec:org802de3c}]{CDG diagnosis}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./figures/cdg_diag.png}
\caption{\label{fig:orgf25d3b5}
CDG diagnosis}
\end{figure}
\end{frame}

\section{PMM2-CDG (CDG-1a)}
\label{sec:org7dd8b5f}

\begin{frame}[label={sec:org456a18d}]{Clinical Presenation}
\begin{itemize}
\item CDG-Ia accounts for 70\% CDGs
\item The nervous system is affected in all patients
\item most other organs are involved in a variable way
\item neurological symptoms include:
\begin{itemize}
\item alternating internal strabismus and other abnormal eye movements
\item axial hypotonia, psychomotor disability, ataxia and hyporeflexia.
\end{itemize}
\item After infancy, symptoms include retinitis pigmentosa, stroke-like episodes, \textpm{} epilepsy.
\item 1st year variable feeding problems anorexia, vomiting, diarrhoea \(\to\) failure to thrive.
\item Other features are:
\begin{itemize}
\item variable dysmorphism, which may include large ears, abnormal
subcutaneous adipose tissue distribution, inverted nipples,
\item mild to moderate hepatomegaly, skeletal abnormalities and hypogonadism.
\end{itemize}
\item Some infants develop a pericardial effusion \textpm{} cardiomyopathy.
\item At the other end of the clinical spectrum are patients with a very
mild phenotype - no dysmorphic features, slight intellectual disability.
\end{itemize}
\end{frame}

\begin{frame}[label={sec:org7eb739a}]{Metabolic Derangement}
\begin{itemize}
\item PMM2-CDG is due to the deficiency of PMM2
\begin{itemize}
\item principal isozyme of PMM
\end{itemize}
\item Phosphomannomutase (PMM) 2 catalyses the second committed step in the synthesis of GDP-mannose
\begin{itemize}
\item mannose-6-phosphate \(\to\) mannose-1-phosphate, occurs in the cytosol
\end{itemize}
\item GDP-mannose is the donor of the mannose units used in the ER to
assemble the dolichol-pyrophosphate oligosaccharide precursor
\item defect \(\to\) hypoglycosylation
\item deficiency and/or dysfunction of numerous glycoproteins, including:
\begin{itemize}
\item serum proteins thyroxin-binding globulin, haptoglobin, clotting factor XI, antithrombin III, cholinesterase
\item lysosomal enzymes
\item membranous glycoproteins
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:orgd8aa217}]{Metabolic Derangement}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./figures/pmm.png}
\caption{\label{fig:orga926bc3}
PMM2}
\end{figure}
\end{frame}

\begin{frame}[label={sec:orgac8648b}]{Genetics}
\begin{itemize}
\item AR, PMM2
\item \(\ge\) 107 mutations identified
\item The most frequent mutation (c.422G>A) causes an R141H substitution
\begin{itemize}
\item present in 75\% of Caucasian patients
\item not compatible with life in the homozygous state.
\item frequency in Belgian as high as 1 in 50.
\end{itemize}
\item The incidence of PMM2 deficiency is not known;
\begin{itemize}
\item in Sweden it has been estimated at 1 in 40,000.
\end{itemize}
\end{itemize}
\end{frame}

\begin{frame}[label={sec:org887d5fd}]{Diagnostic Tests}
\begin{itemize}
\item \(\uparrow\) transaminases, hypoalbuminaemia, hypocholesterolaemia, and
tubular proteinuria.
\item Transferrin IEF
\item To confirm the diagnosis, the activity of PMM should be measured in
leukocytes or fibroblasts.
\begin{itemize}
\item\relax [2-H\(^{\text{3}}\)]mannose-6-phosphate
\end{itemize}
\item PMM activity in fibroblasts can be normal
\end{itemize}
\end{frame}

\begin{frame}[label={sec:org50c23de}]{Treatment}
\begin{itemize}
\item No effective treatment is available.
\item The promising finding that mannose is able to correct glycosylation
in fibroblasts with PMM2 deficiency could not be substantiated in patients.
\end{itemize}
\end{frame}

\section{MPI-CDG (CDG-1b)}
\label{sec:orgbd3243f}

\begin{frame}[label={sec:org96ec884}]{MPI-CDG (CDG-1b)}
\begin{itemize}
\item Phosphomannose isomerase deficiency
\end{itemize}
\begin{center}
\includegraphics[width=0.4\textwidth]{./figures/pmm.png}
\end{center}

\begin{itemize}
\item Prevalence: \textless{} 1/1,000,000
\item AR, MPI
\item onset in infancy, neonatal

\item cyclic vomiting, profound hypoglycemia, failure to thrive, liver
fibrosis, gastrointestinal complications
\begin{itemize}
\item protein-losing enteropathy with hypoalbuminaemia, life-threatening
intestinal bleeding of diffuse origin
\end{itemize}
\item thrombotic events protein C and S deficiency, low anti-thrombine III levels
\item neurological development and cognitive capacity is usually normal.
\item treated effectively with oral mannose supplementation
\item can be fatal if untreated
\end{itemize}
\end{frame}

\section{MGAT2-CDG (CDG-IIa)}
\label{sec:org54c6d3c}

\begin{frame}[label={sec:orge33fdc6}]{MGAT2-CDG (CDG-IIa)}
\begin{itemize}
\item N-acetylglucosaminyltransferase 2 deficiency
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.2\textwidth]{./figures/gntII.jpg}
\caption{\label{fig:org5422be8}
N-acetylglucosaminyltransferase 2}
\end{figure}

\begin{itemize}
\item AR, MGAT2
\item Prevalence \textless{}1/1,000,000
\item onset in infancy, neonatal
\item facial dysmorphism: large, posteriorly rotated ears with prominent
antihelices, convex nasal ridge, open mouth, large and crowded
teeth
\item stereotypic hand movements, seizures, and varying degrees of
developmental delay.
\item A bleeding tendency is also observed due to diminished platelet
aggregation.
\end{itemize}
\end{frame}
\end{document}